Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Interest Expenses (2020 - 2022)

Inhibikase Therapeutics (IKT) has disclosed Interest Expenses for 3 consecutive years, with $5.0 as the latest value for Q1 2022.

  • Quarterly Interest Expenses fell 99.96% to $5.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $5.0 through Dec 2022, down 99.97% year-over-year, with the annual reading at $19923.0 for FY2021, 32.24% down from the prior year.
  • Interest Expenses for Q1 2022 was $5.0 at Inhibikase Therapeutics, down from $158.0 in the prior quarter.
  • The five-year high for Interest Expenses was $11797.0 in Q1 2021, with the low at $5.0 in Q1 2022.
  • Average Interest Expenses over 3 years is $5481.1, with a median of $7139.0 recorded in 2020.
  • The sharpest move saw Interest Expenses surged 58.88% in 2021, then crashed 99.96% in 2022.
  • Over 3 years, Interest Expenses stood at $7139.0 in 2020, then plummeted by 97.79% to $158.0 in 2021, then crashed by 96.84% to $5.0 in 2022.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $5.0, $158.0, and $157.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.